TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23400279

Group type: EXPERIMENTAL
Intervention: Rating and ranking task
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Balance sheet
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Discrete choice experiment
Number of subjects: 911

Group type: COMPARATOR
Intervention: Rating and ranking
Number of subjects: 911
Study: 21442823

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) assisted general anesthesia (group T)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (group G)
Number of subjects: 40
Study: 19692805

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment directed to the large intestine meridian (LI 8 to LI 10)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham laser acupuncture directed to the large intestine meridian (LI 8 to LI 10)
Number of subjects: 60
Study: 17109680

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Number of subjects: 203

Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b (both doses) plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 2 and 3)
Number of subjects: 203
Study: 14720526

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 44
Study: 11722967

Group type: EXPERIMENTAL
Intervention: High-energy prenatal supplementation
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group (no high-energy prenatal supplementation)
Number of subjects: 472
Study: 9394976

Group type: EXPERIMENTAL
Intervention: Inducible nitric oxide synthase (iNOS) expression in allergic contact dermatitis (n=8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inducible nitric oxide synthase (iNOS) expression in irritant contact dermatitis (n=8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal controls (n=6)
Number of subjects: 22
Study: 7967105

Group type: EXPERIMENTAL
Intervention: Gd-DTPA enhanced MRI
Number of subjects: 25

Group type: COMPARATOR
Intervention: Contrast CT
Number of subjects: 25
Study: 3652000

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 10 mg/m2 single intravenous dose
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Mitoxantrone in five consecutive daily fractions of 2 mg/m2
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Vinblastine continuous intravenous infusion of 1.2 mg/m2 daily for 5 days
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Mitoxantrone and vinblastine combination
Number of subjects: 156
Study: 31049136

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NO session)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo supplementation (PL session)
Number of subjects: 14
Study: 26410977

Group type: EXPERIMENTAL
Intervention: Practical demonstration group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Written instruction group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study: 23252809

Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sober group
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 87
Study: 21498279

Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast medium (LOCM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Iso-osmolar contrast medium (IOCM)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both LOCM and IOCM
Number of subjects: 92
Study: 19386449

Group type: EXPERIMENTAL
Intervention: Vibration plus resistance (VR)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Resistance only (RG)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-exercising control (CG)
Number of subjects: 55
Study: 16776732

Group type: EXPERIMENTAL
Intervention: Transitions photochromic spectacle lenses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clear spectacle lenses
Number of subjects: 50
Study: 12631557

Group type: EXPERIMENTAL
Intervention: Asimadoline 0.15 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Asimadoline 1.5 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 11111815

Group type: EXPERIMENTAL
Intervention: Surface treated catheters (Spi‐Argent, Spire Corporation, Bedford, MA, U.S.A.; n = 78 total; n = 32 acute catheters, n = 46 long‐term catheters)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Untreated catheters (n = 92 total; n = 40 acute catheters, n = 52 long‐term catheters)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Surface treated catheters
Number of subjects: 135
Study: 9171807

Group type: EXPERIMENTAL
Intervention: Node-link mapping enhanced counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 0
Study: 8438618

Group type: EXPERIMENTAL
Intervention: 1-3 x 10(9) c.f.u. of lyophilized vaccine, administered in three oral inoculations
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Single application of the total dose for primary immunization or booster
Number of subjects: 143
Study: 3503114

Group type: EXPERIMENTAL
Intervention: Pindolol 1% twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 28882061

Group type: EXPERIMENTAL
Intervention: Exercise training (N=23)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (N=11)
Number of subjects: 34
Study: 27155917

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: In vitro colon model
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: In vitro hepatic models
Number of subjects: 72
Study: 24357403

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience V)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Bare-metal stent (Multi-Link Vision)
Number of subjects: 215
Study: 22539077

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL, 595 nm) treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated keloids)
Number of subjects: 26
Study: 20812009

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 15586

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 15586
Study: 18550554

Group type: EXPERIMENTAL
Intervention: BP stent
Number of subjects: 605

Group type: COMPARATOR
Intervention: PP stent
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: PF stent
Number of subjects: 605
Study: 16026014

Group type: COMPARATOR
Intervention: Low intensity training (60 minutes per week for two weekly training sessions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Middle intensity training (2 1/2 hours of training per week for 5 weekly training sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low intensity training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Middle intensity training
Number of subjects: 20
Study: 12053882

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron before anaesthesia
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron at the end of anaesthesia
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 11922260

Group type: EXPERIMENTAL
Intervention: Method B (silicone impression material in a custom acrylic tray)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Method A (transparent vacuum stent material)
Number of subjects: 6
Study: 9833299

Group type: EXPERIMENTAL
Intervention: Intermittent ondansetron (24 mg i.v. q 12 h/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion ondansetron (8 mg i.v. loading dose followed by a continuous infusion of 2 mg/h per day)
Number of subjects: 66
Study: 8074600

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Number of subjects: 92
Study: 2690549

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 15
Study: 30415646

Group type: EXPERIMENTAL
Intervention: Written prayer technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal daily schedules writing)
Number of subjects: 90
Study: 28758542

Group type: EXPERIMENTAL
Intervention: Camp Group (CG) - six-week day-camp weight-loss programme followed by a family-based supportive programme with four meetings during the succeeding 46 weeks
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Camp Group (CG)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard Group (SG) - weekly two-hour exercise session for six weeks
Number of subjects: 115
Study: 25938778

Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF) for 24 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 23055001

Group type: COMPARATOR
Intervention: Methylphenidate treatment in a 2-week, double-blind, placebo-controlled trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 22050863

Group type: EXPERIMENTAL
Intervention: Training of general practitioners (GPs) in identifying palliative patients and delivering structured proactive palliative care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consulting an expert in palliative care regarding each palliative patient's tailored care plan.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 18649556

Group type: EXPERIMENTAL
Intervention: Microetching prior to acid-etching
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional acid-etching
Number of subjects: 64
Study: 16838235

Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream (topical iontophoretic application)
Number of subjects: 200
Study: 12946072

Group type: EXPERIMENTAL
Intervention: Ultrasound for 10 minutes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Masserann trephining bur (4‐mm‐deep gutter cut)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 10874684

Group type: EXPERIMENTAL
Intervention: Neuronavigation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional operations
Number of subjects: 52
Study: 9106687

Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia combined with chemotherapy and irradiation (HCR therapy) followed by surgery
Number of subjects: 88

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia combined with chemotherapy and irradiation (HCR therapy) plus surgery
Number of subjects: 88
Study: 8195847

Group type: EXPERIMENTAL
Intervention: Brodimoprim (BDP) 400 mg loading dose followed by 200 mg once a day
Number of subjects: 519

Group type: COMPARATOR
Intervention: Amoxicillin (AMX) 750 mg t.i.d
Number of subjects: 519
Study: 29759925

Group type: EXPERIMENTAL
Intervention: Metronidazole 500mg orally every eight hours for seven days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 96
Study: 27075370

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion with a hyrax-type expander, activated twice a day for 15 days to obtain 7.5 mm of palatal expansion, left in situ for six months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment, only observation).
Number of subjects: 20
Study: 24993326

Group type: EXPERIMENTAL
Intervention: Artiflex phakic IOL (Ophtec BV) - Group A
Number of subjects: 46

Group type: COMPARATOR
Intervention: PRK‐MMC - Group B
Number of subjects: 46
Study: 21808075

Group type: EXPERIMENTAL
Intervention: Lingual two-dimensional (2D) technique, 25 patients (19 females and 6 males)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Labial straightwire (SW) technique, 25 patients (20 females and 5 males)
Number of subjects: 50
Study: 20456813

Group type: EXPERIMENTAL
Intervention: Healthy diet+PS (2 g/d of PS)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Free diet+PS (2 g/d of PS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy diet
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Free diet+PS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Healthy diet+PS
Number of subjects: 84
Study: 18556683

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (Infliximab and Placebo) after surgery
Number of subjects: 21
Study: 16020941

Group type: EXPERIMENTAL
Intervention: Persons with dementia
Number of subjects: 121

Group type: COMPARATOR
Intervention: Persons without dementia
Number of subjects: 121
Study: 12449166

Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 18 microg b.i.d.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 microg t.i.d.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 10599658

Group type: EXPERIMENTAL
Intervention: 1 500-mg tablet of levofloxacin (group 1, 22 patients)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 500-mg tablets of levofloxacin (group 2, 23 patients)
Number of subjects: 45
Study: 7794081

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (Fluorouracil, cisplatin, and 4500 cGy over 5 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 43
Study: 2020773

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen combined with nitroimidazoles as a radiation sensitiser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen combined with induced anaemia
Number of subjects: 0
Study: 7075651

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31809224

Group type: EXPERIMENTAL
Intervention: DRL_RI
Number of subjects: 151

Group type: COMPARATOR
Intervention: RMP
Number of subjects: 151
Study: 29941380

Group type: EXPERIMENTAL
Intervention: 200 mg of ibuprofen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 600 mg of ibuprofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27855099

Group type: EXPERIMENTAL
Intervention: Community-based intervention provided by Accredited Social Health Activists (ASHAs) comprising group-based education and support for self-management of blood pressure.
Number of subjects: 14500

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 14500
Study: 24104511

Group type: EXPERIMENTAL
Intervention: Year-long behavioral intervention
Number of subjects: 192
Study: 22094472

Group type: EXPERIMENTAL
Intervention: Brisk walking for 2 hours at ∼50% maximal oxygen uptake
Number of subjects: 12
Study: 19180214

Group type: EXPERIMENTAL
Intervention: Agility training group (trained 4 times per week for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (did not participate in agility training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study: 17524266

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg once daily for 12 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) for 52 weeks (Group B)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) for 40 weeks followed by placebo for 12 weeks (Group C)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) for 52 weeks (Group A and B)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) for 52 weeks (Group C)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) for 156 weeks
Number of subjects: 83
Study: 15174920

Group type: EXPERIMENTAL
Intervention: Endovascular AAA repair
Number of subjects: 76

Group type: COMPARATOR
Intervention: Open AAA repair
Number of subjects: 76
Study: 12241832

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 5477

Group type: COMPARATOR
Intervention: Captopril (50 mg three times daily)
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 5477

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 5477
Study: 9767241

Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured allogeneic keratinocyte sheets and compression bandages
Number of subjects: 27

Group type: COMPARATOR
Intervention: Compression only
Number of subjects: 27
Study: 8205603

Group type: EXPERIMENTAL
Intervention: TCV-116 (2.5 mg and greater)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TCV-116 (repeated administration, once-daily for 8 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TCV-116 (single doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TCV-116 (first 24 hours post-administration)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TCV-116 (repeated administration)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TCV-116
Number of subjects: 36
Study: 2913958

Group type: EXPERIMENTAL
Intervention: Tioconazole
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 2

Group type: COMPARATOR
Intervention: Miconazole nitrate
Number of subjects: 2
Study: 30561840

Group type: EXPERIMENTAL
Intervention: Baclofen (GABA B receptor agonist)
Number of subjects: 24
Study: 31026250

Group type: EXPERIMENTAL
Intervention: Palonosetron (PG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ondansetron (OG)
Number of subjects: 200
Study: 29040481

Group type: EXPERIMENTAL
Intervention: Closed-suction neck drain
Number of subjects: 40

Group type: COMPARATOR
Intervention: No neck drain (control)
Number of subjects: 40
Study: 26122756

Group type: EXPERIMENTAL
Intervention: Active go/no-go training with high-energy density snack foods
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control go/no-go training with non-food stimuli
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 83
Study: 24933773

Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Chlor‐XTRA Vista
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Hypoclean
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 6% sodium hypochlorite/17% EDTA
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 17% EDTA (used at the end of root canal preparation)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Positive control (single gutta‐percha cone without sealer)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Negative control (obturated in the same way as experimental groups)
Number of subjects: 155
Study: 23046330

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted CAS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Stand-alone CAS
Number of subjects: 22
Study: 19281966

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 202

Group type: COMPARATOR
Intervention: Suppression
Number of subjects: 202
Study: 17488800

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg daily for 6 weeks
Number of subjects: 16
Study: 16054412

Group type: EXPERIMENTAL
Intervention: Low normal protein content (LNP) diet (10 E%; 0.9 g protein/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High normal protein content (HNP) diet (20 E%; 1.8 g protein/kg body weight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low normal protein content (LNP) diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: High normal protein content (HNP) diet
Number of subjects: 12
Study: 12398257

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg during week 1, 100 mg during week 2, 150 mg during weeks 3, 4, and 5)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10390029

Group type: EXPERIMENTAL
Intervention: Euphoria (positive condition of the Velten Mood Induction Procedure)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dysphoria (negative condition of the Velten Mood Induction Procedure)
Number of subjects: 60
Study: 7880710

Group type: EXPERIMENTAL
Intervention: Fuzzy control of isoflurane concentration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Human control of isoflurane concentration
Number of subjects: 10
Study: 2223676

Group type: EXPERIMENTAL
Intervention: Hospitalization for bed rest
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 118